126 related articles for article (PubMed ID: 19366069)
21. Multidrug resistance-related phenotype and apoptosis-related protein expression in ovarian serous carcinomas.
Yakirevich E; Sabo E; Naroditsky I; Sova Y; Lavie O; Resnick MB
Gynecol Oncol; 2006 Jan; 100(1):152-9. PubMed ID: 16198399
[TBL] [Abstract][Full Text] [Related]
22. Ovarian carcinomas in endometriosis: an immunohistochemical and comparative genomic hybridization study.
Mhawech P; Kinkel K; Vlastos G; Pelte MF
Int J Gynecol Pathol; 2002 Oct; 21(4):401-6. PubMed ID: 12352189
[TBL] [Abstract][Full Text] [Related]
23. Molecular characterization of 103 ovarian serous and mucinous tumors.
Vereczkey I; Serester O; Dobos J; Gallai M; Szakács O; Szentirmay Z; Tóth E
Pathol Oncol Res; 2011 Sep; 17(3):551-9. PubMed ID: 21136228
[TBL] [Abstract][Full Text] [Related]
24. Serous psammocarcinoma of the ovary: a case report and review of literature.
Giordano G; Gnetti L; Milione M; Piccolo D; Soliani P
Gynecol Oncol; 2005 Jan; 96(1):259-62. PubMed ID: 15589614
[TBL] [Abstract][Full Text] [Related]
25. Expression of p16, p53, CD24, EpCAM and calretinin in serous borderline tumors of the ovary.
Aktaş IY; Buğdayci M; Usubütün A
Turk Patoloji Derg; 2012; 28(3):220-30. PubMed ID: 23011824
[TBL] [Abstract][Full Text] [Related]
26. High grade serous intraepithelial carcinoma arising in a benign ovarian serous cyst - a bridge too far?
Ramanayake N; Russell P; Yang V
Pathology; 2018 Aug; 50(5):485-489. PubMed ID: 29960723
[No Abstract] [Full Text] [Related]
27. Biological markers in pT1 and pT2 ovarian cancer with lymph node metastases.
Concin N; Hefler L; van Bavel J; Mueller-Holzner E; Zeimet A; Daxenbichler G; Speiser P; Hacker N; Marth C
Gynecol Oncol; 2003 Apr; 89(1):9-15. PubMed ID: 12694648
[TBL] [Abstract][Full Text] [Related]
28. P53, bcl-2, and nm23 expressions in serous ovarian tumors: correlation with the clinical and histopathological parameters.
Arik D; Kulaçoğlu S
Turk Patoloji Derg; 2011 Jan; 27(1):38-45. PubMed ID: 21469425
[TBL] [Abstract][Full Text] [Related]
29. Ovarian psammocarcinoma with peritoneal implants.
Cobellis L; Pezzani I; Cataldi P; Bome A; Santopietro R; Petraglia F
Eur J Obstet Gynecol Reprod Biol; 2003 Apr; 107(2):217-9. PubMed ID: 12648875
[TBL] [Abstract][Full Text] [Related]
30. Borderline serous papillary tumor arising in a paraovarian cyst.
Terada T
Eur J Obstet Gynecol Reprod Biol; 2010 Jun; 150(2):215-6. PubMed ID: 20188456
[No Abstract] [Full Text] [Related]
31. Apoptosis in epithelial ovarian tumors.
Preethi TR; Chacko P; Kesari AL; Praseeda I; Chellam VG; Pillai MR
Pathol Res Pract; 2002; 198(4):273-80. PubMed ID: 12049336
[TBL] [Abstract][Full Text] [Related]
32. The prognostic significance of the immunohistochemical expression of p53, bcl-2, c-erb B-2 and cathepsin-D in ovarian cancer patients receiving platinum with cyclophosphamide or paclitaxel chemotherapy.
Protopapas A; Diakomanolis E; Bamias A; Milingos S; Markaki S; Papadimitriou C; Dimopoulos AM; Michalas S
Eur J Gynaecol Oncol; 2004; 25(2):225-9. PubMed ID: 15032288
[TBL] [Abstract][Full Text] [Related]
33. The "Far Left" of the Morphologic Spectrum of Ovarian High-grade Serous Carcinoma: Case Report of a Purely Noninvasive High-grade Serous Carcinoma Mimicking an Ovarian Serous Borderline Tumor.
Katsakhyan L; Baraban EG; Dumoff KL; Burger RA; Parikh R; Cooper K
Int J Gynecol Pathol; 2021 Mar; 40(2):175-179. PubMed ID: 32168063
[TBL] [Abstract][Full Text] [Related]
34. The development of high-grade serous carcinoma from atypical proliferative (borderline) serous tumors and low-grade micropapillary serous carcinoma: a morphologic and molecular genetic analysis.
Dehari R; Kurman RJ; Logani S; Shih IeM
Am J Surg Pathol; 2007 Jul; 31(7):1007-12. PubMed ID: 17592266
[TBL] [Abstract][Full Text] [Related]
35. [Preliminary study on the relationship between tubal intraepithelial carcinoma of the fimbria and pelvic high-grade serous carcinoma].
Liang Y; Chen XD; Lü BJ; Zhou CY; Zhang XF; Shi HY
Zhonghua Fu Chan Ke Za Zhi; 2011 Oct; 46(10):724-8. PubMed ID: 22321343
[TBL] [Abstract][Full Text] [Related]
36. p53 protein expression in putative precursor lesions of epithelial ovarian cancer.
Hutson R; Ramsdale J; Wells M
Histopathology; 1995 Oct; 27(4):367-71. PubMed ID: 8847068
[TBL] [Abstract][Full Text] [Related]
37. Immunohistochemical localization of c-erbB-2 protein and epidermal growth factor receptor in normal surface epithelium, surface inclusion cysts, and common epithelial tumours of the ovary.
Wang DP; Konishi I; Koshiyama M; Nanbu Y; Iwai T; Nonogaki H; Mori T; Fujii S
Virchows Arch A Pathol Anat Histopathol; 1992; 421(5):393-400. PubMed ID: 1360720
[TBL] [Abstract][Full Text] [Related]
38. Endometrioid adenocarcinoma of the ovary mimicking serous borderline tumor: report of a series of cases.
Mansor S; McCluggage WG
Int J Gynecol Pathol; 2014 Sep; 33(5):470-6. PubMed ID: 25083962
[TBL] [Abstract][Full Text] [Related]
39. [Clinicopathologic study and immunohistochemistry comparison of Pax2, p53 and Ki-67 in low- and high-grade ovarian serous carcinomas].
Shen XX; Yu L; Bi R; Yang WT
Zhonghua Bing Li Xue Za Zhi; 2011 Aug; 40(8):511-6. PubMed ID: 22169637
[TBL] [Abstract][Full Text] [Related]
40. Psammocarcinoma with an aggressive course.
Poggi SH; Bristow RE; Nieberg RK; Berek JS
Obstet Gynecol; 1998 Oct; 92(4 Pt 2):659-61. PubMed ID: 9764653
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
